1. Scrip
  2. >>R&D

Pfizer's India MD On Funding Healthcare Startups

Oncology, Digital Health A Focus

 
• By Vibha Ravi

Pfizer’s India managing director, S Sridhar, talks to Scrip about funding startups focused on oncology and digital health, via the CSR route. Two such startups, SiCureMi and Tinkertech, are close to commercialization. Meanwhile, Pfizer's pact with MPP will allow the COVID-19 antiviral Paxlovid to find its way to India and 94 other low- and middle-income countries

Image of Pfizer Ltd Managing Director S Sridhar
Pfizer's India Managing Director S Sridhar • Source: Pfizer Ltd

Pfizer Ltd. (India) draws on the expertise of its parent Pfizer Inc. to launch innovative drugs in India – the latter spent $13.8bn or nearly 45% of sales on research and development (R&D) during 2021. 

While the Indian subsidiary’s own R&D expenditure was nil during FY21, Pfizer Ltd is keen to support start-ups as part of its corporate social responsibility (CSR) initiatives in the country

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.